Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine
FM Russell, A Balloch, MLK Tang, JR Carapetis, P Licciardi, J Nelson, AWJ Jenney, L Tikoduadua, L Waqatakirewa, J Pryor, GB Byrnes, YB Cheung, EK Mulholland
VACCINE | ELSEVIER SCI LTD | Published : 2009
The aim was to identify an appropriate infant pneumococcal vaccination strategy for resource poor countries. Fijian infants received zero, one, two, or three doses of 7-valent pneumococcal conjugate vaccine (PCV) in early infancy. Following three PCV doses, geometric mean concentration (GMC) to all seven serotypes were > or = 1.0 microg/mL, and >85% of children achieved antibody levels > or = 0.35 microg/mL at 18 weeks. Following two doses, GMC were lower for 6B, 14, and 23F, but higher for 19F compared with three doses. Following a single dose, significant responses were seen for all serotypes post-primary series compared with the unvaccinated. By 12 months, differences between two and thre..View full abstract
Related Projects (1)
Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
The authors wish to sincerely thank all the FiPP staff and families participating in the study. Funding was provided by NIAID and the National Health and Medical Research Council. Pneumovax (R) was kindly donated by CSL Biotherapies, Australia. The co-administered Tritanrix (R)-HepB (R) and Hiberix (R) vaccines were kindly donated by GlaxoSmithKIine.Contributors: The authors wish to sincerely thank the many other people who contributed to the study including: Amanda O'Brien, Kathryn Bright, Samantha Colqhoun, Amy Bin Chen, Timothy Gemetzis, Amy Auge, Katherine Gilbert, Evan Willis, Philip Greenwood, Beth Temple, Vanessa Johnston, Porter Anderson, Brian Greenwood, George Siber, David Klein, Elizabeth Horigan, and Farukh Khambaty.Conflict of interest: There are no potential conflicts of interests for any of the contributing authors. MLKT has been a consultant/advisor for Wyeth Vaccines.